









Markets
/
Stocks
/
nasdaq-imrn
/

Immuron Ltd

IMRN

1.810USD

+0.010+0.56%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

423.47MMarket Cap

--P/E TTM



Immuron Ltd

1.810

+0.010+0.56%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-18

Key Insights

Its valuation is considered fairly valued,and institutional recognition is very low. Over the past 30 days, multiple analysts have rated the company as a . The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

144 / 175

Overall Ranking

578 / 4721

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

5.000

Target Price

+177.78%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Immuron Limited is an Australia-based biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases. It operates through two segments: Research and development (R&D), and Hyperimmune products. The R&D segment is focused on R&D projects performed in Australia and the United States. Hyperimmune products segment is engaged in Travelan and Protectyn activities which occur predominantly in Australia, the United States and Canada. Its flagship products consist of Travelan and Protectyn. Travelan is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting traveler’s diarrhea and is sold in pharmacies throughout Australia. Protectyn is sold online and in health practitioner clinics and is marketed as an immune supplement to help maintain a healthy digestive function and liver. Its clinical programs include Travelan (IMM-124E), IMM-529, and CampETEC.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 309.06% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 11.07M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 40.55.

Overvalued

The company’s latest PE is -56.16, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 6.10K shares, decreasing 86.78% quarter-over-quarter.

Financial Health

Currency: USD Updated: 2025-09-18

There is no financial score for this company; the Pharmaceuticals industry's average is 7.84. Its latest quarterly revenue reached 6.46M, representing a year-over-year increase of 86.64%, while its net profit experienced a year-over-year increase of 32.14%.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-18

The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is -55.85, which is 4.44% below the recent high of -58.33 and -15.75% above the recent low of -64.64.

Score

Industry at a Glance

Previous score

1.20

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 144/175

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-18

There is no earnings forecast score for this company; the Pharmaceuticals industry's average is 7.78. The average price target for Immuron Ltd is 5.00, with a high of 5.00 and a low of 5.00.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-18

The company’s current price momentum score is 6.91, which is higher than the Pharmaceuticals industry's average of 6.64. Sideways: Currently, the stock price is trading between the resistance level at 1.95 and the support level at 1.63, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.91

Change

-0.57

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.018

Neutral

RSI(14)

49.043

Neutral

STOCH(KDJ)(9,3,3)

16.976

Sell

ATR(14)

0.084

High Vlolatility

CCI(14)

-51.411

Neutral

Williams %R

76.471

Sell

TRIX(12,20)

0.283

Sell

StochRSI(14)

7.741

Oversold

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

1.846

Sell

MA10

1.860

Sell

MA20

1.838

Sell

MA50

1.774

Buy

MA100

1.786

Buy

MA200

1.853

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-18

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

UBS Financial Services, Inc.

-100.00%

Rhumbline Advisers Ltd. Partnership

5.94K

Morgan Stanley & Co. LLC

-100.00%

BNP Paribas Securities Corp. North America

-100.00%

SBI Securities Co., Ltd.

10.00

Wells Fargo Advisors

150.00

HRT Financial LP

-100.00%

Morgan Stanley Smith Barney LLC

-100.00%

Two Sigma Investments, LP

-100.00%

Global Wealth Management Investment Advisory, Inc.

-100.00%

Risk Assessment

Currency: USD Updated: 2025-09-18

The company’s current risk assessment score is 2.91, which is lower than the Pharmaceuticals industry's average of 4.07. The company's beta value is 0.66. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.